Evolus, Inc. $EOLS Shares Sold by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. reduced its stake in Evolus, Inc. by 12.9%, owning approximately 0.56% of the company after selling 53,757 shares, valued at $4.35 million.
• In related transactions, Evolus’ CMO sold 5,722 shares while Director Brady Stewart increased his stake by 51.17% by purchasing 30,000 shares.
• Analysts have varied ratings for Evolus, with recent targets ranging from $18.00 to $22.00, while the stock is currently rated as a "Moderate Buy."

Goldman Sachs Group Inc. reduced its holdings in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 12.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 361,920 shares of the company's stock after selling 53,757 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.56% of Evolus worth $4,354,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in EOLS. AlphaQuest LLC acquired a new position in Evolus in the first quarter valued at $39,000. State of Wyoming increased its stake in Evolus by 988.1% in the first quarter. State of Wyoming now owns 3,754 shares of the company's stock valued at $45,000 after purchasing an additional 3,409 shares during the last quarter. IFP Advisors Inc increased its stake in Evolus by 99.0% in the first quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock valued at $113,000 after purchasing an additional 4,691 shares during the last quarter. Rafferty Asset Management LLC acquired a new stake in Evolus during the fourth quarter worth about $115,000. Finally, Man Group plc acquired a new stake in Evolus during the fourth quarter worth about $121,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Evolus

In related news, Director Brady Stewart bought 30,000 shares of the stock in a transaction dated Friday, August 15th. The stock was acquired at an average price of $6.82 per share, for a total transaction of $204,600.00. Following the completion of the purchase, the director owned 88,629 shares in the company, valued at $604,449.78. This represents a 51.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $7.51, for a total value of $42,972.22. Following the completion of the sale, the chief marketing officer owned 89,949 shares of the company's stock, valued at approximately $675,516.99. This trade represents a 5.98% decrease in their position. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by company insiders.

Evolus Stock Down 2.0%

Shares of EOLS stock traded down $0.13 during trading hours on Friday, reaching $6.29. The company had a trading volume of 2,320,120 shares, compared to its average volume of 923,458. The company has a debt-to-equity ratio of 22.00, a quick ratio of 1.86 and a current ratio of 2.27. Evolus, Inc. has a twelve month low of $5.71 and a twelve month high of $17.82. The company has a market capitalization of $406.84 million, a P/E ratio of -6.42 and a beta of 1.07. The stock's fifty day simple moving average is $7.78 and its 200 day simple moving average is $9.63.

Analyst Ratings Changes

Several brokerages have commented on EOLS. Needham & Company LLC restated a "hold" rating and set a $22.00 price target on shares of Evolus in a research note on Wednesday, August 6th. Wall Street Zen lowered Evolus from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. HC Wainwright dropped their price target on Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Finally, BTIG Research restated a "buy" rating and set a $18.00 price target on shares of Evolus in a research note on Monday, September 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $21.25.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.